Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study
Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study
复制标题
DOI：
10.1016/j.jfms.2011.01.005
复制
发表时间：
2011-06-01
影响因子：
1.7
通讯作者：
Dow, Steven W.
中科院分区：
文献类型：
--
作者：
Quimby, Jessica M.;Webb, Tracy L.;Dow, Steven W.
探讨了自体肾内间充质干细胞（MSC）治疗猫慢性肾脏病（CKD）的可行性。6只猫（2只健康，4只患有CKD）通过超声引导接受单次单侧肾内注射自体骨髓来源或脂肪组织来源的MSC（bmMSC或aMSC）。在注射前、注射后第7天和第30天通过核血管造影测定最小数据库和肾小球滤过率（GFR）。肾内注射未引起即刻或长期不良反应。接受aMSC的两只患有CKD的猫经历了GFR的适度改善和血清肌酐浓度的轻度降低。尽管肾内MSC注射对CKD猫可能有好处，但实施这种方法所需的镇静剂和干预措施的数量可能会妨碍广泛的临床应用。我们的结论是，MSC可以通过超声引导下肾内注射安全地转移到猫，但MSC治疗的替代来源和途径应进行调查。(C)2011年ISFM和AAFP。由爱思唯尔有限公司出版。保留所有权利。
The feasibility of autologous intrarenal mesenchymal stem cell (MSC) therapy in cats with chronic kidney disease (CKD) was investigated. Six cats (two healthy, four with CKD) received a single unilateral intrarenal injection of autologous bone marrow-derived or adipose tissue-derived MSC (bmMSC or aMSC) via ultrasound guidance. Minimum database and glomerular filtration rate (GFR) via nuclear scintigraphy were determined pre-injection, at 7 days and at 30 days post-injection. Intrarenal injection did not induce immediate or long-term adverse effects. Two cats with CKD that received aMSC experienced modest improvement in GFR and a mild decrease in serum creatinine concentration. Despite the possible benefits of intrarenal MSC injections for CKD cats, the number of sedations and interventions required to implement this approach would likely preclude widespread clinical application. We concluded that MSC could be transferred safely by ultrasound-guided intrarenal injection in cats, but that alternative sources and routes of MSC therapy should be investigated. (C) 2011 ISFM and AAFP. Published by Elsevier Ltd. All rights reserved.